TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

of severe respiratory failure. Clin Infect Dis 2006;43:1247-56.
1.1075 Koepke R et al. Global occurrence of infant botulism, 1976-2006. Pediatrics 2008;122:e73-82.
1.1076 Rowley AH et al. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther
2010;8:197-203.
1.1077 Pinna GS et al. Kawasaki disease: an overview. Curr Opin Infect Dis 2008;21:263-70.
1.1078 Son MB et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to
2006. Pediatrics 2009;124:1-8.
1.1079 Newburger JW et al. Diagnosis, treatment and long-term management of Kawasaki disease. Circulation
2004;110:2747-71.
1.1080 Burns JC et al. Kawasaki syndrome. Lancet 2004;364:533-44.
1.1081 Mason WH et al. Kawasaki syndrome. Clin Infect Dis 1999;28:169-87.
1.1082 Burgner D et al. Kawasaki disease: what is the epidemiology telling us about the etiology? Int J
Infect Dis 2005;9:185-94.
1.1083 Esper F et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis
2005;191:499-502.
1.1084 Kobayashi T et al. risk stratification in the decision to include prednisolone with intravenous immunoglobulin
in primary therapy of Kawasaki disease. Pediatr Infect Dis J 2009;28:498-502.
1.1085 Shulman ST. Is there a role for corticosteroids in Kawasaki disease? J Pediatr 2003;142:601-3.
1.1086 Sundel RP et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized
trial. J Pediatr 2003;142:611-6.
1.1087 Newburger JW et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki
disease. N Engl J Med 2007;356:663-75.
1.1088 Burns JC. The riddle of Kawasaki disease. N Engl J Med 2007;356:659-61.
1.1089 Furukawa T et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Arch Dis Child 2008;93:142-6.
1.1090 Wallace CA et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics
2000;105:e78.
1.1091 Hashino K et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study
of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211-7.
1.1092 Carapetis JR et al. Acute rheumatic fever. Lancet 2005;366:155-68.
1.1093 Cilliers AM. Rheumatic fever and its management. Br Med J 2006;333:1153-6.
1.1094 Lever A et al. Sepsis: definition, epidemiology, and diagnosis. Br Med J 2007;335:879-83.
1.1095 Holmes CL et al. Vasopressin. Semin Respir Crit Care Med 2004;25:705-11.
1.1096 Russell JA et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J
Med 2008;358:877-87.
1.1097 Levy MM et al. The Surviving Sepsis Campaign: results of an international guideline-based performance
improvement program targeting severe sepsis. Intensive Care Med 2010;36:222-31.
1.1098 Garnacho-Montero J et al. Impact of adequate empirical antibiotic therapy on the outcome of patients
admitted to the intensive care unit with sepsis.Crit Care Med 2003;31:2742-51.
1.1099 MacArthur RD et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience
from the MONARCS trial. Clin Infect Dis 2004;38:284-8.
1.1100 Kumar A et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical
determinant of survival in human septic shock.Crit Care Med 2006;34:1589-96.
1.1101 Ferrer R et al. Effectiveness of treatments for severe sepsis. A prospective, multicenter, observational
study. Am J Respir Crit Care Med 2009;180:861-6.
1.1102 Nguyen HB et al. Implementation of a bundle of quality indicators for the early management of severe
sepsis and septic shock is associated with decreased mortality.Crit Care Med 2007;35:1105-12.
1.1103 Drgona L et al. The need for aminoglycosides in combination with β-lactams for high-risk febrile neutropaenic
patients with leukaemia. Eur J Cancer Suppl 2007;5:13-22.
1.1104 Paul M et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination
therapy for sepsis. Cochrane Database Syst Rev 2006;1:CD003344.
1.1105 Paul M et al. β-lactam monotherapy versus β-lactam aminoglycoside combination therapy for sepsis
in immunocompetent patients: systematic review and meta-analysis of randomised trials. Br Med J
2004;328:668-81.
1.1106 Safdar N et al. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia?
A meta-analysis. Lancet Infect Dis 2004;4:519-27.
1.1107 Paul M et al. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever
with neutropenia: systematic review and meta-analysis. Br Med J 2003;326:1111-9.
1.1108 Furno P et al. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment
of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002;2:231-42.
1.1109 Rivers E et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl
J Med 2001;345:1368-77.
1.1110 Annane D et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality
in patients with septic shock. J Am Med Assoc 2002;288:862-71.
1.1111 Sligl W et al. Safety and efficacy of corticosteroids for the treatment of septic shock: a systematic review
and meta-analysis. Clin Infect Dis 2009;49:93-101.
1.1112 Minneci PC et al. The effects of steroids during sepsis depend on dose and severity of illness: an updated
meta-analysis. Clin Microbiol Infect 2009;15:308-18.
1.1113 Annane D et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults. A systematic
review. J Am Med Assoc 2009;301:2362-75.
1.1114 Sprung CL et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-
24.
1.1115 Keh D et al. Corticosteroid therapy in patients with severe sepsis and septic shock. Semin Respir
Crit Care Med 2004;25:713-9.
1.1116 Bernard GR et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N
Engl J Med 2001;344:699-709.
1.1117 Abraham E et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N
Engl J Med 2005;353:1332-41.
1.1118 Houston G et al. Activated protein C for the treatment of severe sepsis. Clin Microbiol Infect 2009;
15:319-24.
1.1119 Toussaint S et al. Activated protein C for sepsis. N Engl J Med 2009;361:2646-52.
1.1120 Nadel S et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised
controlled trial. Lancet 2007;369:836-43.